{
    "ticker": "ENTA",
    "name": "Enanta Pharmaceuticals, Inc.",
    "description": "Enanta Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapeutics for viral infections and liver diseases. Founded in 1998, Enanta is headquartered in Watertown, Massachusetts. The company specializes in the discovery and development of small molecule drugs for the treatment of infectious diseases, leveraging its expertise in medicinal chemistry and virology. Enanta is particularly recognized for its contributions to the field of hepatitis C, having played a significant role in the development of several key antiviral therapies. The company's proprietary drug candidates include EDP-235, an oral antiviral candidate for the treatment of COVID-19, and EDP-514, aimed at treating chronic hepatitis B virus infections. Enanta's mission is to address unmet medical needs in infectious diseases by advancing its robust pipeline and fostering collaborations with other pharmaceutical companies and research institutions. The company is committed to scientific excellence and innovation, positioning itself as a leader in the biotechnology sector.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Watertown, Massachusetts, USA",
    "founded": "1998",
    "website": "https://www.enanta.com",
    "ceo": "Jay R. Luly",
    "social_media": {
        "twitter": "https://twitter.com/enantapharma",
        "linkedin": "https://www.linkedin.com/company/enanta-pharmaceuticals"
    },
    "investor_relations": "https://investors.enanta.com",
    "key_executives": [
        {
            "name": "Jay R. Luly",
            "position": "CEO"
        },
        {
            "name": "Robert A. McCauley",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Antiviral Therapeutics",
            "products": [
                "EDP-235",
                "EDP-514"
            ]
        }
    ],
    "seo": {
        "meta_title": "Enanta Pharmaceuticals, Inc. | Innovative Antiviral Therapies",
        "meta_description": "Explore Enanta Pharmaceuticals, Inc., a leader in antiviral therapeutics focused on unmet medical needs in infectious diseases. Learn about their innovative pipeline and commitment to scientific excellence.",
        "keywords": [
            "Enanta Pharmaceuticals",
            "Biotechnology",
            "Antiviral Therapeutics",
            "Hepatitis C",
            "COVID-19",
            "EDP-235",
            "EDP-514"
        ]
    },
    "faq": [
        {
            "question": "What does Enanta Pharmaceuticals specialize in?",
            "answer": "Enanta Pharmaceuticals specializes in developing innovative therapeutics for viral infections and liver diseases."
        },
        {
            "question": "Who is the CEO of Enanta Pharmaceuticals?",
            "answer": "Jay R. Luly is the CEO of Enanta Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Enanta Pharmaceuticals headquartered?",
            "answer": "Enanta Pharmaceuticals is headquartered in Watertown, Massachusetts, USA."
        },
        {
            "question": "What are some of Enanta's key products?",
            "answer": "Enanta's key products include EDP-235 and EDP-514, both aimed at treating viral infections."
        },
        {
            "question": "When was Enanta Pharmaceuticals founded?",
            "answer": "Enanta Pharmaceuticals was founded in 1998."
        }
    ],
    "competitors": [
        "GILD",
        "MRNA",
        "PFE",
        "BMY"
    ],
    "related_stocks": [
        "AMGN",
        "ABBV",
        "VRTX",
        "REGN"
    ]
}